68Ga-HBED-CC-Exendin-4靶向GLP-1受体PET/CT定位胰岛素瘤:与68Ga-NOTA-Exendin-4的头对头比较
19例内源性高胰岛素性低血糖患者连续2天内分别接受68Ga-HBED-CC-exendin-4与68Ga-NOTA-exendin-4 PET/CT,两种示踪剂检测灵敏度均为100%,肿瘤SUVmax前者显著低于后者,但肿瘤/本底比值无显著差异,前者肾脏摄取较后者降低约30%。
要点
- 68Ga-HBED-CC-exendin-4与68Ga-NOTA-exendin-4定位胰岛素瘤的灵敏度均为100%。
- 注射后50分钟肿瘤SUVmax前者20.01±9.41显著低于后者31.78±15.46(P<0.001)。
- 前者肾脏SUVmean 42.21±5.79较后者58.58±10.06降低约30%(P<0.001)。
核心结论
- 68Ga-HBED-CC-exendin-4是定位胰岛素瘤的有效示踪剂,检出率和肿瘤/本底比值与68Ga-NOTA-exendin-4相似,且肾脏摄取显著更低,可能有利于检出邻近左肾的肿瘤。
研究设计与样本
- 本研究纳入19例内源性高胰岛素性低血糖患者,在连续2天内分别进行68Ga-HBED-CC-exendin-4 PET/CT和68Ga-NOTA-exendin-4 PET/CT检查,评估两种示踪剂定位胰岛素瘤的诊断效能并测量病灶、正常胰腺本底、肾脏和膀胱的SUV。
主要发现
- 68Ga-HBED-CC-exendin-4与68Ga-NOTA-exendin-4 PET/CT的检出率等效,灵敏度均为100%。
- 注射后50分钟,68Ga-HBED-CC-exendin-4组肿瘤SUVmax为20.01±9.41,显著低于68Ga-NOTA-Exendin-4组的31.78±15.46(P<0.001)。
- 两种示踪剂的肿瘤/本底比值无显著差异(8.61±3.57 vs 8.18±3.38,P=0.326)。
- 在行动态PET/CT的患者中,两种示踪剂注射后最早4分钟即可见病灶。
- 68Ga-HBED-CC-exendin-4的肾脏摄取较68Ga-NOTA-exendin-4降低约30%(注射后50分钟SUVmean 42.21±5.79 vs 58.58±10.06,P<0.001)。
关键数值与推荐
- 68Ga-HBED-CC-exendin-4与68Ga-NOTA-exendin-4定位胰岛素瘤的灵敏度均为100%。
- 注射后50分钟肿瘤SUVmax:68Ga-HBED-CC-exendin-4组20.01±9.41 vs 68Ga-NOTA-exendin-4组31.78±15.46(P<0.001)。
- 肿瘤/本底比值:68Ga-HBED-CC-exendin-4组8.61±3.57 vs 68Ga-NOTA-exendin-4组8.18±3.38(P=0.326)。
- 注射后50分钟肾脏SUVmean:68Ga-HBED-CC-exendin-4组42.21±5.79 vs 68Ga-NOTA-exendin-4组58.58±10.06(P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Modifying glucagon-like peptide-1 receptor (GLP-1R)-targeted PET agent to achieve faster renal clearance and preserved high affinity to GLP-1R is clinically relevant. The aim of this study is to assess the performance of a newly developed GLP-1R-targeted agent, 68 Ga-HBED-CC-exendin-4 in localizing insulinoma, and its biodistribution, as compared with previously introduced 68 Ga-NOTA-exendin-4. PATIENTS AND METHODS: Nineteen patients with endogenous hyperinsulinemic hypoglycemia were enrolled and referred for 68 Ga-HBED-CC-exendin-4 PET/CT and 68 Ga-NOTA-exendin-4 PET/CT within 2 consecutive days. Diagnostic performance of the 2 tracers in localizing insulinoma was evaluated, and SUV of the lesion, normal pancreas background, kidneys, and bladder were measured. RESULTS: 68 Ga-HBED-CC-exendin-4 and 68 Ga-NOTA-exendin-4 PET/CT exhibited an equivalent efficacy in detection rate (both sensitivity of 100%). Although SUV max of the tumor in 68 Ga-HBED-CC-exendin-4 was significantly lower than that in 68 Ga-NOTA-exendin-4 (20.01 ± 9.41 vs 31.78 ± 15.46, P < 0.001) at 50 minutes postinjection, there was no significant difference in the tumor-to-background ratio between the 2 agents (8.61 ± 3.57 vs 8.18 ± 3.38, P = 0.326), and the lesions could be visible as early as 4 minutes postinjection for both agents in patients who underwent dynamic PET/CT. In addition, 68 Ga-HBED-CC-exendin-4 exhibited approximately 30% decrease of the renal accumulation compared with 68 Ga-NOTA-exendin-4 (SUV mean , 42.21 ± 5.79 vs 58.58 ± 10.06 at 50 minutes, P < 0.001). CONCLUSIONS: 68 Ga-HBED-CC-exendin-4 is an effective agent for localizing insulinoma showing similar detectability and tumor-to-background ratio compared with 68 Ga-NOTA-exendin-4. Notably, 68 Ga-HBED-CC-exendin-4 exhibits significantly lower renal uptake than 68 Ga-NOTA-exendin-4, which might potentially benefit the detection of the tumors adjacent to the left kidneys.
引用
- Li L, Wang G, Wang J, et al. Glucagon-Like Peptide-1 Receptor-Targeted PET/CT With 68 Ga-HBED-CC-Exendin-4 in Localizing Insulinoma : A Head-to-Head Comparison to 68 Ga-NOTA-Exendin-4. Clin Nucl Med. 2024. PMID: 39499011. doi:10.1097/RLU.0000000000005533
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。